Openings stll available in Dr. Kaiser's clinical study

March 8, 2012

Hi, all.

Dr. Jon Kaiser has asked me to let people know that there are still a few

openings available in his clinical study. This study is available to people who

have ME/CFS and live in the San Francisco area or are able to travel there.

Participation in the study is free, and involves only one visit to Dr. Kaiser's

office, which is in Mill Valley, just north of San Francisco.

The study involves taking a combined nutritional and antioxidant supplement and

a currently available medication for one month, and responding to some questions

and rating of symptoms.

To be eligible for the study, it is required that a person not have significant

fibromyalgia, a history of heart disease, uncontrolled high blood pressure,

major depression, or ulcer disease.

The combined supplement and medication consist of the K-PAX Immune Support

formula with a small dosage of methylphenidate (also known as Ritalin).

Some people have expressed concern about the inclusion of Ritalin in this

treatment.

Dr. Kaiser emphasizes that the dosage of Ritalin in the treatment is small

compared to the dosages commonly used, and that when Ritalin is combined with

K-PAX Immune Support, its effect is much different from when it is used alone.

In this combination, he finds that it serves as a " metabolic catalyst, " working

together with the nutritional supplements. Dr. Kaiser has been using this

combination to treat some of his ME/CFS patients for as long as two years, with

good results. He reports that over time he decreases the use of the Ritalin in

favor of the nutritional supplement, but that it is important at the beginning

of the treatment.

For people who experience benefit in this clinical study and wish to continue

the treatment after one month, there is opportunity to do so.

Dr. Kaiser has extensive experience in treating HIV/AIDS patients, and has also

been

treating ME/CFS patients for 20 years. In addition to his medical practice, he

is the CEO of K-PAX Pharmaceuticals. If this clinical study continues to

produce positive results, he plans to use it as the basis for a more extensive

clinical trial, in cooperation with other ME/CFS clinicians and researchers.

The long-term goal is to be able to make this type of ME/CFS treatment available

to the general medical community.

For more information or to enroll in the trial, please email Anne Lahaderne at

a.lahaderne@... or call her at (415) 381-7655. I am not financially

associated with Dr.Kaiser or with K-PAX Pharmaceuticals.

Recommended Posts